Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
NCT06777628
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Liver Cancer, Adult
Interventions
DRUG:
Immunochemotherapy combined with antiangiogenic
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna